Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/183804
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Houédé, N. | - |
dc.contributor.author | Locker, G. | - |
dc.contributor.author | Lucas, C. | - |
dc.contributor.author | Soto Parra, H. | - |
dc.contributor.author | Basso, U. | - |
dc.contributor.author | Spaeth, D. | - |
dc.contributor.author | Tambaro, R. | - |
dc.contributor.author | Basterretxea, L. | - |
dc.contributor.author | Morelli, F. | - |
dc.contributor.author | Theodore, C. | - |
dc.contributor.author | Lusuardi, L. | - |
dc.contributor.author | Lainez, N. | - |
dc.contributor.author | Guillot, A. | - |
dc.contributor.author | Tonini, G. | - |
dc.contributor.author | Bielle, J. | - |
dc.contributor.author | García del Muro Solans, Xavier | - |
dc.date.accessioned | 2022-03-04T18:14:34Z | - |
dc.date.available | 2022-03-04T18:14:34Z | - |
dc.date.issued | 2016-09-23 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | http://hdl.handle.net/2445/183804 | - |
dc.description.abstract | Background: Platinum-based systemic chemotherapy is considered the backbone for management of advanced urothelial carcinomas. However there is a lack of real world data on the use of such chemotherapy regimens, on patient profiles and on management after treatment failure. Methods: Fifty-one randomly selected physicians from 4 European countries registered 218 consecutive patients in progression or relapse following a first platinum-based chemotherapy. Patient characteristics, tumor history and treatment regimens, as well as the considerations of physicians on the management of urothelial carcinoma were recorded. Results: A systemic platinum-based regimen had been administered as the initial chemotherapy in 216 patients: 15 in the neoadjuvant setting, 61 in adjuvant therapy conditions, 137 in first-line advanced setting and 3 in other conditions. Of these patients, 76 (35 %) were initially considered as cisplatin-unfit, mainly because of renal impairment (52 patients). After platinum failure, renal impairment was observed in 44 % of patients, ECOG Performance Status ≥ 2 in 17 %, hemoglobinemia < 10 g/dL in 16 %, hepatic metastases in 13 %. 80 % of these patients received further anticancer therapy. Immediately after failure of adjuvant/neoadjuvant chemotherapy, most subsequent anticancer treatments were chemotherapy doublets (35/58), whereas after therapy failure in the advanced setting most patients receiving further anticancer drugs were treated with a single agent (80/114). After first progression to chemotherapy, treatment decisions were mainly driven by Performance Status and prior response to chemotherapy (>30 % patients). The most frequent all-settings second anticancer therapy regimen was vinflunine (70 % of single-agent and 42 % of all subsequent treatments), the main reasons evoked by physicians (>1 out of 4) being survival benefit, safety and phase III evidence. Conclusion: In this daily practice experience, a majority of patients with urothelial carcinoma previously treated with a platinum-based therapy received a second chemotherapy regimen, most often a single agent after an initial chemotherapy in the advanced setting and preferably a cytotoxic combination after a neoadjuvant or adjuvant chemotherapy. Performance Status and prior response to chemotherapy were the main drivers of further treatment decisions. | - |
dc.format.extent | 1 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s12885-016-2782-3 | - |
dc.relation.ispartof | BMC Cancer, 2016, vol. 16, num. 1, p. 752-752 | - |
dc.relation.uri | https://doi.org/10.1186/s12885-016-2782-3 | - |
dc.rights | cc-by (c) Houédé, N. et al., 2016 | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Càncer de bufeta | - |
dc.subject.classification | Cisplatí | - |
dc.subject.classification | Epidemiologia | - |
dc.subject.other | Bladder cancer | - |
dc.subject.other | Cisplatin | - |
dc.subject.other | Epidemiology | - |
dc.title | Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 680113 | - |
dc.date.updated | 2022-03-04T18:14:35Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27664126 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
680113.pdf | 545.31 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License